Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection

Expert Review of Clinical Pharmacology

Volumn 7, Issue 6, 2014, Pages 691-704

  Flanagan, Stuart ^a   Crawford Jones, Andrew ^a   Orkin, Chloe ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

co infection; directly acting antivirals; hepatitis C; HIV; NS3 4A protease inhibitors; simeprevir

Indexed keywords

AMINOTRANSFERASE; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BILIRUBIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DACLATASVIR; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHODIESTERASE V INHIBITOR; PROTON PUMP INHIBITOR; RIBAVIRIN; SEDATIVE AGENT; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TMC 647055; UNCLASSIFIED DRUG; VIRUS RNA; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; COUGHING; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSOMNIA; LIVER CIRRHOSIS; MIXED INFECTION; MONOTHERAPY; MOOD DISORDER; MYALGIA; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ANIMAL; COINFECTION; COMPLICATION; DRUG DESIGN; DRUG INTERACTION; HIV INFECTIONS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; COINFECTION; DRUG DESIGN; DRUG INTERACTIONS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; SULFONAMIDES;

EID: 84911879740     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.956091     Document Type: Review

References (48)

1. Choo Q, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62
2. Hepatitis C, fact sheet No. 164, 2000. World Health Organization; Geneva: 2000
3. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infection in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm infect 2004;80:326-7
4. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1(3):559-68
5. Chen S, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
6. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009;83:7366-74
7. Cohn J, Piot P, Swan T, et al. UNITAID can address HCV/HIV co-infection. Lancet 2013;381(9867):628
8. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: a collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50(10): 1387-96
9. Rosenthal EG, Pialoux N, Bernard C, et al. Liver related mortality in HIV infected patients between 1995-2003 in the French GERMIVIC joint study group network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-8
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5):346-55
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomised trial. Lancet 2001;358(9286):958-65
12. Cunningham M, Foster G. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012;5(2):139-51
13. Sitole M, Silva M, Sponer L, et al. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. J Clin Ther 2013; 35(2):190-7
14. British HIV Association. Management of hepatitis viruses in adults infected with HIV. HIV Med 2013;14(Suppl 4):1-s
15. Alkhouri N. Protease inhibitors: Silver bullets for chronic hepatitis C infection? Cleve Clin J Med 2012;79(3):213-22
16. Levin J. Adherence with Telaprevir BID versus every 8 hour dosing in treatment-naïve HCV-infected patients: results from the Phase III OPTIMIZE study. Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL);Amsterdam, The Netherlands; 2013
17. Welsch C, Wang Y, Zettler M, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50(6):1709-18
18. Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011;54(3):781-8
19. Johnson & Johnson. Available from: www. jnj.com/news/all/OLYSIO-simeprevir- Receives-FDA-Approval-for-Combination- Treatment-of-Chronic-Hepatitis-C
20. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. abstract 1413 Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; 2013
21. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) plus PEG-IFN/ ribavirin in HCV genotype-1/HIV- 1 coinfection (Study C212). abstract 24 Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
22. UK medicines information. Available from: www.ukmi.nhs.uk/applications/ndo/ record-view-open.asp?newDrugID=5112 [Last accessed 15 May 2014]
23. Moreno C, Berg T, Tanwandee T, et al. A Phase IIa, Open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6. abstract 895 Program and abstracts of the 59th American Association of the Study of Liver Diseases (AASLD);San Francisco, CA, USA;2008
24. Foster GR, Jacobson IM, Dore GJ, et al. Simeprevir (TMC435) with peginterferon/ ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naïve European patients in the quest-1 and quest-2 phase III trials. abstract 1127 Program and abstracts of the 49th European Association for the Study of the Liver (EASL); London, UK; 2014
25. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138(3):913-21
26. Sherwat AI. Simeprevir medical review. food and drug administration center for drug evaluation and research. office of drug evaluation. Maryland, USA: 2013
27. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2013;49(1):138-47
28. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. abstract 1425 Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; 2013
29. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase iii trial. Gastroenterology 2014;5085(14):293-5
30. Rouan MC, Snoeys S, Ouwerkerk-Mahadevan R, et al. Combination therapy with simeprevir and TMC647055/low dose Ritonavir: dose anticipation using PBPK modeling and dose optimisation un healthy subjects. Proceedings of the 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Cambridge, MA, USA;2013
31. Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. J Antivir Ther 2011;16(7):1021-33
32. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56(6):1247-53
33. Lenz O, Vijgen L, Moreno C, et al. Virologic response and characterisation of HCV genotypes 2-6 under TMC435 monotherapy. Proceedings of International Workshop on HIV and Hepatitis Drug Resistance and Curative Strategies; Los Cabos, Mexico; 2011
34. Huisman M, Snoeys J, Monbaliu J, et al. TMC435 in combination with peginterferon and ribavirin in treatment naïve HCV genotype 1 patients. Final analysis of the PILLAR Phase IIb Study (TMC435-C205). Poster 278 presented at 61st Annual Meeting of the American Assosiation for the Study of Liver Diseases (AASLD); Boston, MA, USA; 2010
35. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58(6):1918-29
36. Zeuzem S, Berg T, Gane E, et al. Tmc435 In HCV genotype 1 patients who have failed previous pegylated interferon/ ribavirin treatment: final Svr24 results of the aspire trial. abstract 2 Program and abstracts of the 47th European association of the liver meeting; Barcelona, Spain;2012
37. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61(2):219-27
38. Reddy KR, Zeuzem S, Zoulim F, et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. (APASL) 24th Conference of the Asian Pacific Association for the Study of the Liver; 12-15 March 2014; Brisbane, Australia
39. Ouwerkerk-Mahadevan S, Simion A, Mortier A, et al. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. abstract 80 Program and Abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA, USA; 2012
40. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/ without ribavirin in HCV genotype-1 prior null-responder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2). abstract 165 Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; London, UK; 2014
41. Zeuzem S, Hezode C, Bronowicki JP, et al. Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection. Abstract 28LB Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
42. ClinicalTrials.gov. 3 year Follow-up Study in Patients Previously Treated With TMC435 for the Treatment of Hepatitis C (HCV) Infection. Available from: http:// clinicaltrials.gov/ct2/show/record/ NCT01349465 [Last accessed 23rd May 2014]
43. Riviere K. Biopharmaceutics review - simeprevir. Food and drug administration. USA. 2013. Available from: www.accessdata. fda.gov/drugsatfda-docs/nda/2013/ 205123Orig1s000ClinPharmR.pdf [Last accessed 12th May 2014]
44. BHIVA Writing Group. British HIV association guidelines for the treatment of HIV positive adults with antiretroviral therapy 2013. HIV Med 2014;15(Supp 1): 1-45
45. Sulkowski M, Jacobson IM, Ghalib R, et al. Once daily simeprevir (TMC435) plus Sofosbuvir (GS-7977) with or without Ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis. abstract 07 Program and Abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver (EASL). London, England 2014
46. Delaney M, Taylor J, Swan T, et al. Hepatitis C virus: from trials and tribulations to triumph. abstract 6 Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
47. Ferenci P, Nyberg A, Bernstein D, et al. PEARL III: SVR 99% after 12 wks of ABT-450/r/267 + ABT-333 ± RBV in treatment naive HCV GT1b infection. abstract 29LB Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA; 2014
48. Ruane PJ, Ain D, Meshrekey R, et al. Sofosbuvir plus ribavirin, an interferon free regimen, in the treatment of treatment-naïve and treatment-experienced patients with chronic genotype 4 HCV infection. abstract 1243 Program and Abstracts of the 49th Annual Meeting of the European Association for the study of the liver (EASL); London, England; 2014